Effects of Therapy on Urine Neutrophil Gelatinase-Associated Lipocalin in Nondiabetic Glomerular Diseases with Proteinuria
Table 1
Baseline characteristics according to remission status at follow-up.
Baseline characteristics
All patients
By response to treatment
value
Complete remission
Not in remission
Male, (%)
15 (34.9%)
5 (55.6%)
10 (29.4%)
0.143
Age, years
0.409
BMI, kg/m2
0.19
Systolic BP, mmHg
0.52
Diastolic BP, mmHg
0.26
ACEI and/or ARB use
38 (88.3%)
8 (80%)
30 (90.9%)
0.52
Corticosteroids ± immunosuppressive agents (%)
25 (58%)
9 (90%)
16 (48.5%)
0.035
Albumin, g/dL
3.14 (0.59–3.88)
1.86 (0.78–3.88)
3.21 (0.59–3.88)
0.035
Cholesterol, mg/dL
250 (143–669)
338 (150–594)
240 (143–669)
0.060
Serum creatinine, mg/dL
1.21 (0.43–4.17)
1.21 (0.54–1.42)
1.21 (0.43–4.17)
0.141
Baseline GFR, mL/min/1.73 m2
66.2 (12.3–143.4)
77 (54–137)
59 (12–143)
0.09
Proteinuria, g/g creatinine
2.17 (0.09–9.23)
3.06 (0.11–9.23)
2.15 (0.09–9.15)
0.55
Data shown as mean ± SD or median (min–max). considered significant. ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockade; BMI, body mass index; BP, blood pressure; GFR, glomerular filtration rates.